•
Jan 31, 2021

KalVista Q3 2021 Earnings Report

KalVista reported third fiscal quarter results and recent KVD900 Phase 2 clinical trial results as statistically and clinically significant.

Key Takeaways

KalVista Pharmaceuticals reported no revenue for the third fiscal quarter ended January 31, 2021, compared to $1.6 million for the same period in the prior fiscal year. Research and development expenses were $9.1 million, compared to $11.2 million for the same period in the prior fiscal year. Net loss was $10.1 million, or $(0.56) per share, compared to a net loss of $9.3 million, or $(0.52) per share, for the same period in the prior fiscal year. Cash, cash equivalents and marketable securities were $50.3 million as of January 31, 2021, compared to $67.7 million as of April 30, 2020.

Reported positive results for KVD900 in a Phase 2 clinical trial demonstrating statistically and clinically significant responses across primary and secondary endpoints as an oral on-demand treatment for HAE attacks.

The trial met its primary endpoint comparing the time to use of conventional attack treatment within 12 hours on KVD900 versus placebo (p=0.0010) with rates of use at 12 hours of 15.1% following treatment with KVD900 versus 30.2% after placebo.

Closed an upsized public offering of common stock and full exercise of the underwriters’ options to purchase additional shares, resulting in gross proceeds of approximately $222.5 million.

Filed the IND for a Phase 2 clinical trial of KVD824 and expect to initiate that trial in the second quarter of 2021.

EPS
-$0.56
Previous year: -$0.52
+7.7%
Cash and Equivalents
$17.7M
Previous year: $18.6M
-4.8%

KalVista

KalVista

Forward Guidance

KalVista is focused on advancing its oral HAE franchise, including finalizing the Phase 3 program for KVD900 and initiating a Phase 2 clinical trial for KVD824.

Positive Outlook

  • Positive Phase 2 clinical trial results for KVD900 as an oral on-demand therapy for HAE attacks.
  • KVD900 demonstrated statistically and clinically significant responses across primary and secondary endpoints.
  • IND submitted for Phase 2 clinical trial of KVD824 as an oral prophylactic treatment for HAE.
  • Upsized public offering provides sufficient cash to reach KVD900 NDA filing.
  • Advancing oral Factor XIIa inhibitor program for improved HAE treatment.

Challenges Ahead

  • Potential impact of COVID-19 on clinical trials and operations.
  • Risks and uncertainties associated with the safety and efficacy of product candidates.
  • Dependence on successful commencement and completion of clinical studies.
  • Uncertainty in obtaining regulatory approvals for KVD900, KVD824, and other candidates.
  • Risks related to the future progress and potential success of the oral Factor XIIa program.